Skip to main content

Table 4 Pharmacokinetic parameters following nebulization of voriconazole (VRC) and its lipid-polymer hybrid nanoparticles (LPH NPs)

From: Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention

Parameter(s) Lung pharmacokinetics Plasma pharmacokinetics
VRC solution VRC LPH NPs VRC solution VRC LPH NPs
Cmax (μg mL−1) 13.43 ± 3.10 26.29 ± 5.78 6.81 ± 1.11 7.79 ± 2.07
Tmax(h) 0.17 ± 0.00 0.67 ± 0.29 0.39 ± 0.19 1.67 ± 0.38
AUC0-24 (μg mL−1*h) 36.38 ± 5.40 177.75 ± 23.40 33.89 ± 5.05 69.01 ± 10.25
AUC0-∞ (μg mL−1*h) 41.77 ± 6.75 237.51 ± 22.98 35.94 ± 6.11 89.16 ± 16.71
MRT (h) 5.27 ± 1.31 16.46 ± 2.87 7.13 ± 1.03 15.26 ± 3.44
  1. Data expressed as mean ± SD (n = 3)